AHA Statement on 340B Rebate Guidance

Aimee Kuhlman
Vice President, Advocacy and Grassroots
American Hospital Association

July 31, 2025

The AHA looks forward to reviewing HRSA’s 340B rebate guidance in more detail and working with the agency on this issue. However, we are concerned that this guidance authorizes a significant departure from how the 340B program has successfully operated for decades and sets a dangerous precedent for possible harmful expansions in the future. This pilot program is a response to a non-existent program integrity problem that the drug manufacturers have manufactured in the public discourse.

Nevertheless, we appreciate HRSA’s efforts to impose strict guardrails on its limited pilot program. Going forward, it will be essential that HRSA makes certain that the drug companies bear all the costs of implementing these rebate models and that those companies provide discounts expeditiously. Anything else will pose serious financial risks to patients, communities, and the hospitals that care for them.

###